207 related articles for article (PubMed ID: 18321239)
1. Raltegravir: an integrase inhibitor for HIV-1.
Evering TH; Markowitz M
Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH; Markowitz M
Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.
Anker M; Corales RB
Expert Opin Investig Drugs; 2008 Jan; 17(1):97-103. PubMed ID: 18095922
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
[TBL] [Abstract][Full Text] [Related]
6. Treatment of HIV infection with raltegravir.
Chirch LM; Morrison S; Steigbigel RT
Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir.
Croxtall JD; Lyseng-Williamson KA; Perry CM
Drugs; 2008; 68(1):131-8. PubMed ID: 18081377
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
9. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Correll T; Klibanov OM
Pharmacotherapy; 2008 Jan; 28(1):90-101. PubMed ID: 18154479
[TBL] [Abstract][Full Text] [Related]
10. FDA approves raltegravir tablets.
AIDS Patient Care STDS; 2007 Nov; 21(11):889. PubMed ID: 18240897
[No Abstract] [Full Text] [Related]
11. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
12. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
[TBL] [Abstract][Full Text] [Related]
13. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Kravchenko AV
Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir as antiretroviral therapy in HIV/AIDS.
Sharma M; Walmsley SL
Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
[TBL] [Abstract][Full Text] [Related]
17. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
18. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
19. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir: a new antiretroviral class for salvage therapy.
Cahn P; Sued O
Lancet; 2007 Apr; 369(9569):1235-1236. PubMed ID: 17434380
[No Abstract] [Full Text] [Related]
[Next] [New Search]
